-
Insight into FDA Orange Book patents and grasp the pulse of original drugs
Time of Update: 2021-06-05
Therefore, Orange Book patents have become a very important information channel for understanding the original research drugs marketed in the United States.
-
With the escalation of the Sino-US trade war, China may expand access to the Indian drug market
Time of Update: 2021-06-05
, The relevant government agencies of the two sides are actively formulating specific measures to promote Sino-Indian pharmaceutical trade cooperation and allow more Indian drugs to enter the Chinese market.
-
A line of squamous NSCLC!
Time of Update: 2021-06-05
The ORIENT-12 study is a randomized, double-blind, phase III controlled clinical study evaluating the effectiveness and safety of sintilimab or placebo combined with gemcitabine and platinum for the first-line treatment of advanced or metastatic squamous NSCLC (NCT03629925 ), a total of 57 subjects were enrolled.
-
Rituximab "upgraded version"!
Time of Update: 2021-06-05
Due to the impact of biosimilar drugs, sales have begun to decline; Gazyva has always been regarded as an upgraded version of Rituxan, which is Roche's response to the cannibalization of its CD20 market.
-
AstraZeneca China reached a cooperation with Boan Biotechnology on bevacizumab injection
Time of Update: 2021-06-05
Exclusive promotion rights.
It is reported that bevacizumab injection is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting vascular endothelial growth factor (VEGF), which can inhibit its binding to VEGF receptors by binding to VEGF-A.
-
Jinfang Pharmaceutical's KRAS G12C inhibitors apply for clinical Amgen, Novartis and other corporate layouts
Time of Update: 2021-06-05
In July 2019, Mirati Therapeutics and Novartis reached a clinical collaboration to evaluate the combination therapy of MRTX849 and TNO155 (a SHP2 inhibitor) in the treatment of patients with advanced solid tumors with KRAS G12C mutations.
-
Rise across the board!
Time of Update: 2021-06-05
Sales of terminal insulin and similar drugs in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern Due to the high technical barriers to insulin products, the three foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied the dominant position in the domestic insulin market.
-
Qilu Pharmaceutical's new anti-cancer drug imported for USD 235 million applied for clinical application
Time of Update: 2021-06-05
Article source: Pharmaceutical GuanlanAccording to the announcement of the Center for Drug Evaluation (CDE) of the State Drug Administration of China, Qilu Pharmaceutical submitted a clinical trial application for CEND-1 for injection, which was accepted on May 27.
-
Novartis' new-generation drug Beovu Phase 3 MERLIN study: Intraocular inflammation is higher than aflibercept
Time of Update: 2021-06-05
The active pharmaceutical ingredient of Beovu is brolucizumab (RTH258), which is a humanized single-chain antibody fragment (scfv) that targets all types of vascular endothelial growth factor-A (VEGF-A).
-
Zejing Pharmaceutical's Class 1 new drug ``Donafinil Tosylate Tablets'' will soon be approved for advanced hepatocellular carcinoma
Time of Update: 2021-06-05
This new drug marketing application is mainly based on the results of an open, randomized, parallel controlled, multi-center phase II/III clinical study of Donafenib tosylate tablets for the first-line treatment of advanced hepatocellular carcinoma (trial code ZGDH3).
-
No patent compensation period for new drugs approved before May 31!
Time of Update: 2021-06-04
61 527，《》，。，，：2021531（），。，531，5，。 10，《》，《》202161。《》，。《》，，，。，。 ，、、。，。，“”，《》：、、、、，、。 ，、。，“”，：“202010，《》，。，2021531（），。” ，《》。《》，，、、、。，202011272021111。，、、，，。 5，。，，，《》《》，，，。 19 new drugs launched
-
Yiling Pharmaceutical won the "2021 China Brand (Industry) Top Ten Innovative Enterprises"
Time of Update: 2021-06-04
On May 27th, the “China Enterprise News” group, the special issue department of Consumer Daily, the column group of “Discover Brands”, the online version of the People’s Daily Market News Brand Power · Independent Brand Selection Demonstration Project, University of International Business and Economics China International Brand Strategy The 2021 (eighth) Chinese brand influence evaluation results release event jointly sponsored by the Research Center and other units was held in Beijing.
-
How to maintain the safety of medical insurance funds?
Time of Update: 2021-06-04
Song Shigui, deputy director of the Sichuan Provincial Health Commission, introduced that in recent years, the Sichuan Provincial Health Commission has established a joint meeting system with the Provincial Medical Security Bureau and the Provincial Public Security Department to regularly study new situations and problems in fraudulent insurance work.
-
Tianyao: Methylprednisolone sodium succinate for injection passed the consistency evaluation
Time of Update: 2021-06-04
Jinyao Pharmaceutical's methylprednisolone sodium succinate for injection obtained drug registration approval issued by the National Medical Products Administration in November 2012.
In March 2019, Jinyao Pharmaceutical submitted a supplementary application for consistency evaluation to the Drug Evaluation Center of the National Medical Products Administration and was accepted.
-
Health Commission: 23 new confirmed cases and 11 local cases
Time of Update: 2021-06-04
The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on May 31 The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on May 31 The lat
-
"Bethune·Tumor Patient Education" project launched
Time of Update: 2021-06-04
Professor Li Danqing, Department of Thoracic Surgery, Peking Union Medical College Hospital, introduced that a study in the United States showed that if a person smokes 10 to 20 cigarettes a day, the incidence of lung cancer is 15%.
-
New developments in FDA regulations for complex generic drugs
Time of Update: 2021-06-04
In each fiscal year from 2014 to 2020, the FDA has basically listed "complex product equivalence" as the scientific research focus of GDUFA supervision, and strives to improve And promote the research and development of complex generic drugs and the application and approval process to improve the efficiency of complex generic drugs application and listing.
-
The liberalization of the three-child policy has far-reaching impact in these medical fields...
Time of Update: 2021-06-04
In this regard, since the liberalization of the two-child policy, the National Health Statistics Yearbook data has changed significantly: In 2017, the number of outpatient visits in general hospitals in China was 240 million, the proportion of pediatric outpatients in general outpatient visits increased from 8.
-
Drug Administration: Issued the "Administrative Measures for Drug Inspection (Trial)"
Time of Update: 2021-06-04
Medical Network, May 31, May 28, in order to implement the "Drug Administration Law" and the "Vaccine Administration Law", further standardize drug inspection behavior, and promote drug regulatory wo
-
Three kinds of drug instructions including haloperidol tablets add medication information for children
Time of Update: 2021-06-04
People's Daily Online, Beijing, June 2 (Reporter Hongli Sun) A few days ago, the State Food and Drug Administration issued an announcement that haloperidol tablets, risperidone oral preparations and fluoxetine oral preparations can increase the number of children and the dosage as required .
